Right Care, Right Patient, Right Time: 
The Role of Comparative Effectiveness Research

John Bulger, D.O., MBA
April 17, 2019

1

Caring

Geisinger

Putting Clinical Effectiveness Research Into Practice
John B. Bulger, DO, MBA
Chief Medical Officer
Geisinger Health Plan

Challenges with Biologic Medications

High Impact

Spend Outlook

Trend

Costs

0.72% of the claims are driving 35% of total Rx spend

It is predicted that specialty medications will represent 50% of total spend within 2 years

Each year specialty spending is increasing 25 to 40% each year

$4,616 Average monthly cost of a specialty medication

Range: $600 to $30,000 per month

Geisinger

2
Right Care, Right Patient, Right Time:
The Role of Comparative Effectiveness Research

John Bulger, D.O., MBA
April 17, 2019

GHP Biologic Spend & Trend thru March 2019

Care Pathway Development

- Evolution of ProvenCare®, a system approach to population management
- Research current literature, national guidelines and GHS data
- Best Practice Clinical Consensus
  - Safety
  - Reduce unwarranted variation
  - Education
  - Collaboration
- Process evaluation and transformation
- Empowered to drive real change
- Robust reporting capabilities
- Aligned incentives: patient, provider, payer
Features of Successful Payer-Provider Partnerships

ACHP’s Research Identified 5 Best Practices That Health Plans Can Employ to Accelerate the Adoption of Evidence-Based Care.

1. **Build** consensus and commitment to change
2. **Create** a multi-disciplinary team that includes the necessary skill sets, perspectives, and staff roles
3. **Customize** education, tools, and access to specialized knowledge for physicians and for patients
4. **Share** timely and accurate data and feedback in a culture of transparency, accountability, and healthy competition
5. **Align** financial investments with clinical and patient experience goals

Hepatitis C: Managing Total Cost of Care

- “Cure” rates GHP/GHS COE=99.7%
- “Cure” national comparison rates: 85%-90%
- “Cure” rate for GHP/nonGHS ~ 50-70% (manual)
- Process monitors physician compliance of CarePath
- The large volume of cases within the COE has allowed us to determine/tailor:
  - The optimal drugs for treatment
  - The optimal duration of treatment
- Both of these result in lower total cost of care

https://catalyst.nejm.org/geisinger-provencare-hcv-cure/
Hepatitis C Lessons Learned

- A total cost of care, collaborative approach brings higher value
- Patients receive higher quality care
- The total cost of care is decreased
- The goal is to provide this level of care to all patients
  - Scale Center of Excellence by adding capacity and sites
  - Redesign benefits to drive members to Center of Excellence

Thank you!

John B. Bulger, DO, MBA
Chief Medical Officer
Geisinger Health Plan

jbulger@geisinger.edu
@johnbbulger

Thank you to Sandeep Khurana, Kristi Clarke, Julienne Hanley, Jeremy Vilcheck, Mike Evans, Bret Yarczower, Joe Chronowski, Eric Wright, and Michael Gionfriddo for their contribution to the development of the ProvenCare® Hepatitis C program and dissemination.
Report Title: Accelerating Adoption of Evidence-Based Care: Payer-Provider Partnerships

Purpose: To capture best practices used by ACHP member plans in partnering with providers to improve health and enhance patient engagement

Timeline: April 3, 2017 – November 27, 2018

Output: Final report and additional resources at www.transforming-care.org